drugset / Trial / NCT00658008

A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (1)

NCT00658008

Phase 3 Terminated 501 enrolled Pfizer
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a 10-week trial that evaluates the efficacy and safety of PD 0332334 in subjects, ages from 18 to 65, with generalized anxiety disorder.

Timeline

Start
2008-04
Primary completion
2009-03
Completion
2009-03

Drugs

EvaluationDrugModalityDoseRoute
Subject IMAGABALIN Other / unclassified 75 mg Oral
Subject IMAGABALIN Other / unclassified 175 mg Oral
Subject IMAGABALIN Other / unclassified 225 mg Oral
Comparator Paroxetine Small molecule 20 mg Oral